|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
More than a decade ago claims arose that the RUNX3 member of the RUNX transcription factor family is a major TSG inactivated in gastric cancer, a postulate extended later to other cancers.
|
25641675 |
2015 |
|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter hypermethylation of p16, Runx3, DAPK and CHFR is frequent in gastric cancer.
|
21302620 |
2011 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX3 showed protein silencing in cancer and normal mucosa, compared to inflammatory peritumoural infiltrate in almost all cases, showing a non-lymphocytic predominant pattern and being correlated with epigenetic silencing.Our results show aberrant promoter's methylation in APC, CDH1, CDKN2A, MLH1 and RUNX3 associated with GC, as well as a non-lymphocytic predominant infiltrate with high expression of RUNX3.
|
27566570 |
2016 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined Detection of Plasma ZIC1, HOXD10 and RUNX3 Methylation is a Promising Strategy for Early Detection of Gastric Cancer and Precancerous Lesions.
|
28529617 |
2017 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RT-qPCR was used to detect the expression of MT1JP, miR-214-3p and RUNX3 in tumor tissues and cell lines of GC.
|
29742512 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results provide further evidence that RUNX3 can function as a tumor suppressor and suggest that practical methods to augment RUNX3 function could be useful in treating of some types of gastric cancer.
|
23230322 |
2013 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Runx3 knockouts and stomach cancer.
|
12776174 |
2003 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Runt-related transcription factor 3 (RUNX3) is a candidate tumor suppressor gene whose deficiency is causally related to gastric cancer.
|
19196394 |
2009 |
|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The levels of RUNX3 methylation in serum were in significant concordance with the methylation levels observed in GC tissues (P = .887).
|
22576578 |
2012 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Runt-related transcription factor 3 (Runx3) is an important transcription factor that functions as a tumor suppressor in gastric cancer.
|
29417297 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A great number of genes with promoter methylation have been observed in gastric cancer (GC), among which p16INK4A (p16), Mut L homologue 1 (MLH1), Epithelial-cadherin (E-cadherin), Runt-related transcription factor 3 (RUNX3), adenomatous polyposis coli (APC), O(6)-methylguanine-DNA methyltransferase (MGMT), Ras association domain family 1A (RASSF1A) and Death-associated protein kinase (DAPK) have been extensively studied.
|
22936446 |
2012 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX3 has been suggested to be a tumor suppressor of gastric cancer.
|
16135801 |
2005 |
|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
This study suggests that hypoxia silences RUNX3 by epigenetic histone regulation during the progression of gastric cancer.
|
18850007 |
2009 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer.
|
20176475 |
2010 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our clinical and experimental data provide a novel molecular mechanism for the antitumor activity of RUNX3 and may help design effective therapy targeting RUNX3 pathway to control gastric cancer growth and metastasis.
|
17085650 |
2006 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition to epigenetic changes in the RUNX3 proximal promoter, genetic changes in the distal promoter may be associated with susceptibility to intestinal-type gastric cancer by increasing promoter activity.
|
21523770 |
2011 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-148a can regulate runt-related transcription factor 3 gene expression via modulation of DNA methyltransferase 1 in gastric cancer.
|
23549984 |
2013 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RUNX3 expression was lost in 37 (39%) cases of gastric cancer.
|
19290488 |
2009 |
|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Quantification of epigenetic changes in serum RUNX3 methylation using RTQ-MSP is useful for the detection and monitoring of gastric cancer.
|
19596937 |
2009 |
|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant promoter methylation of Runx3 and CHFR genes may be involved in the carcinogenesis and development of GC and may provide useful clues for the prediction of the malignant behaviors of GC.
|
20300977 |
2011 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings reveal a novel mechanism of RUNX3 for the induction of cell apoptosis in human gastric cancer.
|
24636883 |
2014 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Runt-related transcription factor 3 (RUNX3) is a tumor suppressor of gastric cancer.
|
21135153 |
2011 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that silencing of RUNX3 affects expression of important genes involved in aspects of metastasis including cell adhesion, proliferation, apoptosis, and promoting the peritoneal metastasis of gastric cancer.
|
16166423 |
2005 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found no statistically significant associations between RUNX3 rs6672420 polymorphism and risk of gastric atrophy, nor between these two RUNX3 polymorphisms and the risk of gastric cancer relative to the subjects with gastric atrophy.
|
19728008 |
2009 |
|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
A significant association was observed between RUNX3 promoter methylation and gastric cancer, with an aggregated odds ratio (OR) of 5.63 (95%CI 3.15, 10.07).
|
21867527 |
2011 |